New CBD Research

New CBD Research in the form of a groundbreaking study. This paper has been published recently and can be viewed here.

As posted on the Cannformatics website “The first paper from the ASD Pilot Study that successfully identified Cannabis-Responsive™ biomarkers in children with autism was published by the journal Cannabis and Cannabinoid Research. This is the first study to ever examine the saliva of children with ASD treated with various cannabis/CBD products widely available in California dispensaries. The paper establishes Cannabis-Responsive biomarkers as a universal measurement of cannabis impact. The study positions medical cannabis as the only peer-reviewed published treatment to show a shift towards the physiological range in children with autism.”

In this episode. Ed and Kim talk with Ken Epstein, CCO & Co-Founder of Cannformatics, regarding this groundbreaking paper and what lies ahead for similar research. In spite of today’s cannabis challenges, Cannformatics, a San Francisco-based biotech startup, is conducting groundbreaking clinical studies to remove the confusion and stigma patients face when looking for medical cannabis to improve wellness. The work focuses on developing Cannabis-Responsive biomarkers that can be used to optimize medical cannabis treatments by providing patients and their physicians with data, similar to the data in a blood test, that shows how medical cannabis treatment is impacting the patient’s condition. Cannformatics’ Clinical Advisor and study co-author is Dr. Bonni Goldstein. Dr. Goldstein is a physician and pediatrician who treats children with severe autism and epilepsy, she is also a medical cannabis expert and the author of the book “Cannabis is Medicine.”